TORONTO, ON / ACCESSWIRE / September 24, 2020 / Theralase® Technologies Inc. ("Theralase" or "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and associated drug formulations, provides clarification on how registered shareholders or duly appointed proxyholders who plan to attend the Company's virtual Annual General and Special Meeting ("Meeting") at 4:30pm EDT today can cast their vote at the Meeting.
Only registered shareholders of record as of the close of business on August 21, 2020, the record date for the Meeting, or their duly appointed proxyholders, will be entitled to vote at the virtual Meeting. Shareholders of record and duly appointed proxyholders must, prior to the start of the Meeting (1) access the Meeting by connecting through the link set out below, and (2) connect via phone using the dial-in number set out below in order to be able to vote their shares at the Meeting.
Note: If a registered shareholder has voted their shares online, they do not need to vote them again. The opportunity to vote at the Meeting is only if they wish to change the way their shares are voted.
Access via the following link:
Dial-in using either of these phone numbers: 1-877-407-8037 (toll-free) or (201) 689-8037 (toll)
In terms of the voting procedure, all confirmed registered shareholders and duly appointed proxyholders in attendance via live webcast and teleconference will be able to vote their shares by pressing *1 on their telephones on each of the matters tabled at the Meeting, as will be further explained at the start of the Meeting.
Each registered shareholder or duly appointed proxyholder is entitled to one vote for each common share held as of the close of business on the record date of August 21, 2020.
About Theralase® Technologies Inc.
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers, bacteria and viruses.
Forward Looking Statement:
This news release contains "forward-looking statements" which reflect the current expectations of Company's management for future growth, results of operations, performance, business prospects and opportunities. Such statements include, but are not limited to, statements regarding the Company's proposed development plans with respect to Photo Dynamic Compounds and their drug formulations. Wherever possible, words such as "may", "would", "could", "should", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions; including, with respect to the ability of the Company to: adequately fund, secure the requisite regulatory approvals to commence and successfully complete a Phase II NMIBC clinical study in a timely fashion and implement its commercialization plans. Many factors could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
Chief Financial Officer
416-699-LASE (5273) x 224
SOURCE: Theralase® Technologies Inc.